Amivantamab plus lazertinib vs osimertinib in first-line egfr-mutant advanced non-small cell lung cancer.

Abstract

Introduction: Thefirst line treatment landscape for patients with NSCLC harboring sensitizing EGFRmutations is rapidly evolving. Initially, osimertinib was the one and onlyoption over earlier generation EGFR inhibitors based on the positive PFS and OSresults from the FLAURA study.

Areascovered: Thispaper reviews and compares the pivotal studies that led to the approval ofcombination treatment with a focus on the efficacy and safety of amivantamabplus lazertinib in the front-line setting. The literature reviewed in thispaper primarily includes key studies published in well-established journals andoncological conferences, such as ASCO, ESMO, and NEJM, between 2018 and 2024.

Expertopinion: Recent advancements,including the results of FLAURA-2 and MARIPOSA, have introduced combinationtherapies that demonstrate enhanced efficacy.